Skip to main content

Table 3 Recurrence risk of non-pCR carcinoma according to Clustered Neo-Bioscore

From: Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response

Clustered Neo-Bioscore mTFRa (days) p HRb (CI95%)
Low 1388 Reference
Low-intermediate 1247 <  0.01 2.61 (1.33–5.11)
High-intermediate 618 < 0.01 14.05 (6.78–29.11)
High 433 < 0.01 22.19 (7.70–63.92)
  1. amTFR median time to the first recurrence
  2. bHR Hazard ratio at 3 years